.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Daiichi Sankyo
Cipla
Healthtrust
Queensland Health
McKinsey
Federal Trade Commission
Novartis
Argus Health
US Army

Generated: December 17, 2017

DrugPatentWatch Database Preview

KAZANO Drug Profile

« Back to Dashboard

When do Kazano patents expire, and what generic alternatives are available?

Kazano is a drug marketed by Takeda Pharms Usa and is included in one NDA. There are nine patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and thirty-three patent family members in forty-two countries and sixty-four supplementary protection certificates in twelve countries.

The generic ingredient in KAZANO is alogliptin benzoate; metformin hydrochloride. There are nine drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the alogliptin benzoate; metformin hydrochloride profile page.
Drug patent expirations by year for KAZANO

Pharmacology for KAZANO

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Takeda Pharms UsaKAZANOalogliptin benzoate; metformin hydrochlorideTABLET;ORAL203414-002Jan 25, 2013RXYesYes► Subscribe► SubscribeY► Subscribe
Takeda Pharms UsaKAZANOalogliptin benzoate; metformin hydrochlorideTABLET;ORAL203414-001Jan 25, 2013RXYesNo► Subscribe► Subscribe► Subscribe
Takeda Pharms UsaKAZANOalogliptin benzoate; metformin hydrochlorideTABLET;ORAL203414-002Jan 25, 2013RXYesYes► Subscribe► Subscribe► Subscribe
Takeda Pharms UsaKAZANOalogliptin benzoate; metformin hydrochlorideTABLET;ORAL203414-002Jan 25, 2013RXYesYes► Subscribe► SubscribeYY► Subscribe
Takeda Pharms UsaKAZANOalogliptin benzoate; metformin hydrochlorideTABLET;ORAL203414-001Jan 25, 2013RXYesNo► Subscribe► SubscribeY► Subscribe
Takeda Pharms UsaKAZANOalogliptin benzoate; metformin hydrochlorideTABLET;ORAL203414-001Jan 25, 2013RXYesNo► Subscribe► Subscribe► Subscribe
Takeda Pharms UsaKAZANOalogliptin benzoate; metformin hydrochlorideTABLET;ORAL203414-002Jan 25, 2013RXYesYes► Subscribe► Subscribe► Subscribe
Takeda Pharms UsaKAZANOalogliptin benzoate; metformin hydrochlorideTABLET;ORAL203414-001Jan 25, 2013RXYesNo► Subscribe► Subscribe► Subscribe
Takeda Pharms UsaKAZANOalogliptin benzoate; metformin hydrochlorideTABLET;ORAL203414-001Jan 25, 2013RXYesNo► Subscribe► Subscribe► Subscribe
Takeda Pharms UsaKAZANOalogliptin benzoate; metformin hydrochlorideTABLET;ORAL203414-001Jan 25, 2013RXYesNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: KAZANO

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Takeda Pharms UsaKAZANOalogliptin benzoate; metformin hydrochlorideTABLET;ORAL203414-002Jan 25, 2013► Subscribe► Subscribe
Takeda Pharms UsaKAZANOalogliptin benzoate; metformin hydrochlorideTABLET;ORAL203414-001Jan 25, 2013► Subscribe► Subscribe
Takeda Pharms UsaKAZANOalogliptin benzoate; metformin hydrochlorideTABLET;ORAL203414-001Jan 25, 2013► Subscribe► Subscribe
Takeda Pharms UsaKAZANOalogliptin benzoate; metformin hydrochlorideTABLET;ORAL203414-002Jan 25, 2013► Subscribe► Subscribe
Takeda Pharms UsaKAZANOalogliptin benzoate; metformin hydrochlorideTABLET;ORAL203414-001Jan 25, 2013► Subscribe► Subscribe
Takeda Pharms UsaKAZANOalogliptin benzoate; metformin hydrochlorideTABLET;ORAL203414-002Jan 25, 2013► Subscribe► Subscribe
Takeda Pharms UsaKAZANOalogliptin benzoate; metformin hydrochlorideTABLET;ORAL203414-001Jan 25, 2013► Subscribe► Subscribe
Takeda Pharms UsaKAZANOalogliptin benzoate; metformin hydrochlorideTABLET;ORAL203414-001Jan 25, 2013► Subscribe► Subscribe
Takeda Pharms UsaKAZANOalogliptin benzoate; metformin hydrochlorideTABLET;ORAL203414-002Jan 25, 2013► Subscribe► Subscribe
Takeda Pharms UsaKAZANOalogliptin benzoate; metformin hydrochlorideTABLET;ORAL203414-001Jan 25, 2013► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for KAZANO

Drugname Dosage Strength RLD Submissiondate
alogliptin and metformin hydrochlorideTablets12.5 mg/500 mg and 12.5 mg/1000 mgKazano1/25/2017

Non-Orange Book Patents for Tradename: KAZANO

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,211,205 Pharmaceutical composition► Subscribe
6,172,090 Pharmaceutical composition► Subscribe
6,133,293 Pharmaceutical composition► Subscribe
6,211,207 Pharmaceutical composition► Subscribe
6,599,923 Pharmaceutical composition► Subscribe
6,911,459 Pharmaceutical composition► Subscribe
6,169,100 Pharmaceutical composition► Subscribe
6,384,062 Pharmaceutical composition► Subscribe
7,829,530Method of regulating glucose metabolism, and reagents related thereto► Subscribe
7,906,523Dipeptidyl peptidase inhibitors► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: KAZANO

Country Document Number Estimated Expiration
Australia2493599► Subscribe
China1582149► Subscribe
Canada2559302► Subscribe
European Patent Office2583675► Subscribe
Japan3973280► Subscribe
Japan2014144986► Subscribe
Russian Federation2323004► Subscribe
New Zealand332707► Subscribe
Hong Kong1010484► Subscribe
Slovakia287287► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: KAZANO

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
7Finland► Subscribe
C/GB14/084United Kingdom► SubscribePRODUCT NAME: LINAGLIPTIN; REGISTERED: UK EU/1/11/707/001-011 20110830
1084705/05Switzerland► SubscribePRODUCT NAME: ALOGLIPTIN; REGISTRATION NO/DATE: SWISSMEDIC 62955 21.11.2013
2014042Lithuania► SubscribePRODUCT NAME: VILDAGLIPTINUM; REGISTRATION NO/DATE: EU/1/07/414/001-010, 2007 09 26 EU/1/07/414/018 20070926
00708Netherlands► SubscribePRODUCT NAME: LINAGLIPTIN; REGISTRATION NO/DATE: EU/1/11/707/001-011 20111224
C/GB14/085United Kingdom► SubscribePRODUCT NAME: SAXAGLIPTIN; REGISTERED: UK EU/1/09/545/001-010 20091005
00706Netherlands► SubscribePRODUCT NAME: VILDAGLIPTINE; REGISTRATION NO/DATE: EU/1/07/414/001-017 20070926
1Finland► Subscribe
0140007 00126Estonia► SubscribePRODUCT NAME: ALOGLIPTIIN;REG NO/DATE: EU/1/13/844 23.09.2013
2014 00064Denmark► SubscribePRODUCT NAME: VILDAGLIPTIN; REG. NO/DATE: EU/1/07/414/001-017 20070926
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Cantor Fitzgerald
Colorcon
Cerilliant
Teva
US Department of Justice
McKesson
Citi
Julphar
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot